Zhang Yali, Wang Shaojuan, Wu Yangtao, Hou Wangheng, Yuan Lunzhi, Shen Chenguang, Wang Juan, Ye Jianghui, Zheng Qingbing, Ma Jian, Xu Jingjing, Wei Min, Li Zonglin, Nian Sheng, Xiong Hualong, Zhang Liang, Shi Yang, Fu Baorong, Cao Jiali, Yang Chuanlai, Li Zhiyong, Yang Ting, Liu Lei, Yu Hai, Hu Jianda, Ge Shengxiang, Chen Yixin, Zhang Tianying, Zhang Jun, Cheng Tong, Yuan Quan, Xia Ningshao
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics National Institute of Diagnostics and Vaccine Development in Infectious Diseases School of Public Health & School of Life Sciences Xiamen University Xiamen Fujian 361102 China.
Shenzhen Key Laboratory of Pathogen and Immunity National Clinical Research Center for Infectious Disease Shenzhen Third People's Hospital Second Hospital Affiliated to Southern University of Science and Technology Shenzhen Guangdong 518112 China.
Small Methods. 2021 Feb 15;5(2):2001031. doi: 10.1002/smtd.202001031. Epub 2020 Dec 18.
The ongoing corona virus disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2 infection, has resulted in hundreds of thousands of deaths. Cellular entry of SARS-CoV-2, which is mediated by the viral spike protein and ACE2 receptor, is an essential target for the development of vaccines, therapeutic antibodies, and drugs. Using a mammalian cell expression system, a genetically engineered sensor of fluorescent protein (Gamillus)-fused SARS-CoV-2 spike trimer (STG) to probe the viral entry process is developed. In ACE2-expressing cells, it is found that the STG probe has excellent performance in the live-cell visualization of receptor binding, cellular uptake, and intracellular trafficking of SARS-CoV-2 under virus-free conditions. The new system allows quantitative analyses of the inhibition potentials and detailed influence of COVID-19-convalescent human plasmas, neutralizing antibodies and compounds, providing a versatile tool for high-throughput screening and phenotypic characterization of SARS-CoV-2 entry inhibitors. This approach may also be adapted to develop a viral entry visualization system for other viruses.
由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染引起的2019年冠状病毒病(COVID-19)大流行已导致数十万人死亡。SARS-CoV-2通过病毒刺突蛋白和血管紧张素转换酶2(ACE2)受体进入细胞,这是开发疫苗、治疗性抗体和药物的重要靶点。利用哺乳动物细胞表达系统,开发了一种基因工程荧光蛋白传感器(Gamillus)融合的SARS-CoV-2刺突三聚体(STG),用于探测病毒进入过程。在表达ACE2的细胞中,发现STG探针在无病毒条件下对SARS-CoV-2的受体结合、细胞摄取和细胞内运输的活细胞可视化方面具有优异性能。该新系统允许对COVID-19康复期人类血浆、中和抗体和化合物的抑制潜力及详细影响进行定量分析,为SARS-CoV-2进入抑制剂的高通量筛选和表型表征提供了一种通用工具。这种方法也可用于开发其他病毒的病毒进入可视化系统。